RespireRx Pharmaceuticals (RSPI) 10-Q2019 Q1 Quarterly report

Filed: 20 May 19, 4:06pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Bad

New words: Agreementto, Asia, ASU, ASX, Australia, Becausethere, classification, Concentration, departure, discount, Distinguishing, draft, face, FASB, feature, grantee, grantor, guarantee, Healthcare, Hedging, Impression, inception, joint, key, lender, memorandum, modified, MOU, nonemployee, Payableto, prepay, publicly, purported, remit, Riskto, round, scope, Southeast, speak, tentatively, travel, unreimbursed, venture, Zealand

Removed: abandoned, abandonment, absence, abuse, accruing, acted, addiction, addressed, advanced, agent, analytical, announced, announcement, ASC, began, begun, bifurcation, Biovail, blocker, bring, California, Capitalized, cell, closed, Codification, combined, commenced, commitment, commonly, concurrently, conditioned, confirm, consecutive, Covance, criteria, deduction, delinquent, detail, diligently, director, disagreement, earned, excluding, exit, experienced, expiring, extinguished, federally, field, footnote, forgave, forgive, forgiven, germane, hiring, host, injectable, install, instituted, instrument, insured, intent, International, invested, irrevocable, Irvine, joined, Kathryn, labeling, MacFarlane, mandatorily, methamphetamine, NIDA, November, occurrence, originally, OTC, owe, owing, parent, partial, periodic, permanent, project, promptly, ratio, reacquire, redeemable, redemption, reestablish, renamed, resulted, revalued, review, revise, revised, Robert, Sapirstein, sedative, served, Sharp, sickle, sponsored, SRL, storage, superseded, trained, UCI, unit, unlimited, Valeant, vested, volume, Weingarten, whichever

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RSPI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeff E. Margolis, the Chief Financial Officer of RespireRx Pharmaceuticals Inc. (the “Company”), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

	(i)	The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

	(ii)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

Date: May 20, 2019	By:	/s/ JEFF E. MARGOLIS
		Jeff E. Margolis
		Chief Financial Officer